ReviewStructural heart : the journal of the Heart Team2026
Clinical Failure After Mitral Transcatheter Edge-to-Edge Repair Mechanisms, Outcomes, and Management.
Review in Structural heart : the journal of the Heart Team, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transcatheter repair with edge-to-edge therapy (M-TEER) has been a revolutionary technology for patients with mitral regurgitation (MR). M-TEER is an established safe and effective treatment that alleviates MR, improves quality of life, and, in some patients, improves survival. Nonetheless, a significant number of M-TEER may not have procedural nor clinical success due to a variety of factors, with residual MR and/or mitral stenosis. The clinical manifestation of M-TEER failures may be early or late, with varying degrees of patient impact, ranging from an asymptomatic state to heart failure and poor survival. Because M-TEER patients typically are elderly and with significant morbidity, the management of these clinical failures poses vexing clinical challenges. Herein, we review the incidence and factors that contribute to M-TEER failure, as well as the associated clinical outcomes and management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.